Author

Viktor Ljungström

Harvard UniversityORCID 0009-0005-4633-2099Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Research Focus:variant calling· 2 Assay:whole-genome sequencing· 2 Research Focus:benchmarking· 1 Approach:deep learning· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Hu JiniD· 3 shared Peter J. ParkiD· 3 shared D. GulhaniD· 2 shared Alon GaloriD· 1 shared Antuan V. TraniD· 1 shared Benedikt GeigeriD· 1 shared Benoı̂t RousseauiD· 1 shared Bill H. DiplasiD· 1 shared

Activity by Year

2024-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetic & Genomic Medicine

Hu JinORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genetic & Genomic MedicinemedRxivPreprintApr 15, 2024

Contribution of de novo retroelements to birth defects and childhood cancers

Chong Chu, Viktor Ljungström, Antuan V. Tran…·Peter J. Park

The paper identifies de novo retroelements in birth defects and childhood cancers using whole-genome sequencing data and an improved computational tool.

3 citations

humanwhole-genome sequencing

𝕏 PostBluesky

GenomicsNature GeneticsPeer-reviewedFeb 15, 2024

Accurate and sensitive mutational signature analysis with MuSiCal

Hu Jin, D. Gulhan, Benedikt Geiger…·Peter J. Park

MuSiCal improves mutational signature analysis by outperforming existing methods in discovery and assignment, revealing new signatures and resolving ambiguities in cancer genomes.

54 citationstop 1%

humanwhole-genome sequencing

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintJan 19, 2024

Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures

D. Gulhan, Vinay Viswanadham, Francesc Muyas…·Peter J. Park

The paper identifies mutational signatures SBS26 and SBS54 in MMRD tumors that correlate with immune checkpoint blockade response and survival, suggesting their use as prognostic biomarkers.

4 citations

humanwhole-exome sequencing

𝕏 PostBluesky